Last Updated : November 6, 2019
Details
FilesGeneric Name:
infliximab
Project Status:
Complete
Therapeutic Area:
rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Renflexis
Project Line:
Reimbursement Review
Project Number:
SE0532-000
Call for patient/clinician input closed:
Biosimilar:
Yes
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 | |
|---|---|
| Call for patient input posted | August 04, 2017 |
| Patient group input closed | September 26, 2017 |
Clarification: - Patient input submission received | |
| Patient input summary sent for review to patient input groups | October 05, 2017 |
| Patient group comments on input summary closed | October 13, 2017 |
Clarification: - Patient input summary feedback received | |
| Submission received | September 05, 2017 |
| Submission accepted for review | September 19, 2017 |
| Review initiated | September 20, 2017 |
| Draft CADTH review report(s) sent to sponsor | November 28, 2017 |
| Comments from sponsor on draft CADTH review report(s) received | December 07, 2017 |
| Redaction requests from sponsor on draft CADTH review report(s) received | December 14, 2017 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | January 05, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | January 17, 2018 |
| CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plans | January 29, 2018 |
| Embargo period ended and validation of redacted CADTH review report(s) received | February 12, 2018 |
| CDEC Final Recommendation issued to sponsor and drug plans | February 20, 2018 |
| CDEC Final Recommendation posted | February 22, 2018 |
| Final CADTH review report(s) and patient input posted | April 24, 2018 |
Files
Last Updated : November 6, 2019